Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
62
Views
8
CrossRef citations to date
0
Altmetric
Original Research

More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis

Jin Lu1 Department of Hematology, People’s Hospital, Beijing University, Beijing, People’s Republic of China
,
Jing Lu2 Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, People’s Republic of China
,
Wenming Chen3 Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China
,
Jing Wang1 Department of Hematology, People’s Hospital, Beijing University, Beijing, People’s Republic of China
,
Yuliang Huo4 Data Management Department, Beijing University Clinical Research Institute, Beijing, People’s Republic of China
,
Jian Hou2 Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, People’s Republic of China
&
Xiaojun Huang1 Department of Hematology, People’s Hospital, Beijing University, Beijing, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 3673-3679 | Published online: 08 Nov 2016

References

  • WisloffFAndersenPAnderssonTRHas the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. IEur J Haematol19914753333371761118
  • BergsagelDThe incidence and epidemiology of plasma cell neoplasmsStem Cells199513Suppl 219
  • HewellGMAlexanianRMultiple myeloma in young personsAnn Intern Med19768444414431259287
  • LazarusHMKellermeyerRWAikawaMHerzigRHMultiple myeloma in young men. Clinical course and electron microscopic studies of bone marrow plasma cellsCancer1980466139714007417941
  • GeethaNJayaprakashMRekhanairARamachandranKRajanBPlasma cell neoplasms in the youngBr J Radiol1999728621012101510673955
  • LudwigHDurieBGBolejackVMyeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupBlood200811184039404718268097
  • BladeJKyleRAGreippPRPresenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 yearsBr J Haematol19969323453518639427
  • SchaapveldMVisserOSieslingSSchaarCGZweegmanSVellengaEImproved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989Eur J Cancer201046116016919682891
  • HouJDuXJinJA multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trialJ Hematol Oncol201364123782711
  • SagasterVKaufmannHOdelgaVChromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging SystemEur J Haematol200778322723417253972
  • KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
  • CheemaPKZadehSKukretiVAge 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplantBiol Blood Marrow Transplant200915668669319450753
  • ChongYPKimSKoOBPoor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experienceJ Korean Med Sci200823581982418955788
  • ReeceDEVesoleDHShresthaSOutcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR studyClin Lymphoma Myeloma Leuk201010645846321156462
  • MoreauxJHoseDRemeTCD200 is a new prognostic factor in multiple myelomaBlood2006108134194419716946299
  • Kretz-RommelABowdishKSRationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppressionExpert Opin Biol Ther20088151518081533

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.